FGF R4

FGF R4

FGF R4 Overview

Molecule Name
Fibroblast growth factor receptor 4
Synonyms
FGFR4,CD334,JTK2,MGC20292,TKF
Drug Development Progress
Drugs in Clinical Trials19
Approved Drugs3
Highest Development StageApproved
Target Synonym
CD334 Antigen,EC 2.7.10.1,FGFR-4,Receptor, Fibroblast Growth Factor, Type 4,EC 2.7.10,JTK2,Tyrosine Kinase Related To Fibroblast Growth Factor Receptor,Hydroxyaryl-Protein Kinase,Tyrosylprotein Kinase,EC:2.7.10.1,Fibroblast growth factor receptor 4,CD334,FGFR4,TKF
Background
Fibroblast growth factor receptor 4(FGFR4) is also known as CD334, JTK2, hydroxyaryl-protein kinase, TKF, protein-tyrosine kinase . The FGFR4 gene provides instructions for making a protein called fibroblast growth factor receptor 4. This protein is part of a family of fibroblast growth factor receptors that share similar structures and functions. These receptor proteins play a role in important processes such as cell division, regulating cell growth and maturation, formation of blood vessels, wound healing, and embryo development.The FGFR4 protein interacts with specific growth factors to conduct signals from the environment outside the cell to the nucleus. The nucleus responds to these signals by switching on or off appropriate genes that help the cell adjust to changes in the environment. In response, the cell might divide, move, or mature to take on specialized functions. Although specific functions of FGFR4 remain unclear, studies indicate that the gene is involved in muscle development and the maturation of bone cells in the skull. The FGFR4 gene may also play a role in the development and maintenance of specialized cells (called foveal cones) in the light-sensitive layer (the retina) at the back of the eye.

FGF R4 Product List

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
SC-0011SC-0011Phase 3 ClinicalShijiazhuang Zhikang Hongren New Drug Development Co Ltd
Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Solid tumours; Stomach Neoplasms
Details
AUR-109ODM-203; AUR-109Phase 2 ClinicalOrion Corp
Breast Neoplasms; Carcinoma, Renal Cell; Colorectal Neoplasms; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Ovarian Neoplasms; Pulmonary Fibrosis; Solid tumours; Urinary Bladder Neoplasms
Details
RogaratinibBAY-1163877Phase 2 ClinicalBayer AG
Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Gastrointestinal Stromal Tumors; Metastatic breast cancer; Neoplasms; Sarcoma; Solid tumours; Urinary Bladder Neoplasms
Details
FisogatinibBLU-554; CS-3008Phase 2 ClinicalBlueprint Medicines Corp
Carcinoma, Hepatocellular
Details
BB-102BB-102; BB102Phase 2 ClinicalBroadenbio Co Ltd
Carcinoma, Hepatocellular; Solid tumours
Details
GunagratinibICP-192Phase 2 ClinicalBeijing Tiancheng Pharmaceutical Technology Co Ltd
Biliary Tract Neoplasms; Carcinoma, Transitional Cell; Cholangiocarcinoma; Head and Neck Neoplasms; Lung Neoplasms; Solid tumours; Stomach Neoplasms; Urinary Bladder Neoplasms
Details
IrpagratinibABSK-011Phase 2 ClinicalABbisko Therapeutics Co Ltd
Carcinoma, Hepatocellular; Liver Neoplasms; Solid tumours
Details
BPI-43487BPI-43487Phase 1 ClinicalBetta Pharmaceuticals Co Ltd
Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Solid tumours
Details
HS-236HS-236Phase 1 ClinicalZhejiang Hisun Pharmaceutical Co Ltd
Solid tumours
Details
HS-10340HS-10340Phase 1 ClinicalChangzhou Hengbang Pharmaceutical Co Ltd, Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Hansoh Biomedical Co Ltd
Solid tumours
Details
ICP-105ICP-105Phase 1 ClinicalBeijing Innocare Pharma Tech Co Ltd, Beijing Tiancheng Pharmaceutical Technology Co Ltd, Nanjing Tianyin Jianhua Pharmaceutical Technology Co Ltd
Liver Neoplasms; Solid tumours
Details
ZSP-1241ZSP-1241Phase 1 ClinicalGuangdong Zhongsheng Pharmaceutical Co Ltd, Wuxi Apptec Co Ltd
Biliary Tract Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Neoplasms; Liver Neoplasms; Stomach Neoplasms
Details
H3B-6527H3B-6527Phase 1 ClinicalH3 Biomedicine Inc
Carcinoma, Hepatocellular; Liver Neoplasms
Details
FGFR4-CAR T Cells Therapy(National Cancer Institute)Phase 1 ClinicalNational Cancer Institute
Rhabdomyosarcoma
Details
TYRA-430TYRA-430Phase 1 ClinicalTyra Biosciences Inc
Carcinoma, Hepatocellular; Neoplasms; Solid tumours
Details
SYHX-2005SYHX-2005; SYHX2005Phase 1 ClinicalCspc Ouyi Pharmaceutical Co Ltd
Solid tumours
Details
JAB-6343Phase 1 ClinicalJacobio Pharmaceuticals Co Ltd
Solid tumours
Details
SY-4798SY-4798Phase 1 ClinicalShouyao Holding (Beijing) Co Ltd
Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Solid tumours
Details
ABSK-012ABSK-012; ABSK012Phase 1 ClinicalABbisko Therapeutics Co Ltd
Solid tumours
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyFirst Brand NameFirst Approved CountryFirst IndicationFirst Approved CompanyFirst Approved DateIndicationClinical Trial
Lenvatinib MesilateE-7080; MK-7902; ER-203492-00ApprovedEisai Co LtdKisplyx, Lenvima, Lenvima/Kisplyx, 乐卫玛United StatesThyroid NeoplasmsEisai Inc2015-02-13
Adenocarcinoma; Adenocarcinoma of Lung; Adenocarcinoma, Follicular; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Adenoid Cystic; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Cholangiocarcinoma; Endometrial Neoplasms; Esophageal Neoplasms; Gastrointestinal Stromal Tumors; Glioma; Hepatic Insufficiency; Liver Diseases; Liver Neoplasms; Lymphoma; Melanoma; Neoplasm Metastasis; Neoplasms; Neuroendocrine Tumors; Osteosarcoma; Ovarian Neoplasms; Paraganglioma; Pheochromocytoma; Renal Insufficiency; Solid tumours; Stomach Neoplasms; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Uterine Cervical Neoplasms
Details
FutibatinibTAS-120ApprovedOtsuka Pharmaceutical Co Ltd, Taiho Pharmaceutical Co LtdLYTGOBIUnited StatesCholangiocarcinomaTaiho Oncology Inc2022-09-30
Biliary Tract Neoplasms; Bone Marrow Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Central Nervous System Neoplasms; Cholangiocarcinoma; Endometrial Neoplasms; Esophageal Neoplasms; Lymphoma; Metastatic breast cancer; Neoplasm Metastasis; Neoplasms; Sarcoma; Solid tumours; Stomach Neoplasms
Details
Erdafitinib890E37NHMV; G-024; JNJ-493; JNJ-42756493; TAR-210ApprovedAstex Pharmaceuticals IncBalversa, 博珂United StatesCarcinoma, Transitional CellJanssen Biotech Inc2019-04-12
Adenocarcinoma; Bile Duct Neoplasms; Bone metastases; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Central Nervous System Neoplasms; Ependymoma; Esophageal Neoplasms; Glioma; Hepatic Insufficiency; Hepatoblastoma; Histiocytic Sarcoma; Histiocytosis, Langerhans-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Medulloblastoma; Metastatic breast cancer; Multiple Myeloma; Neoplasms; Neoplasms, Germ Cell and Embryonal; Neuroblastoma; Neuroectodermal Tumors, Primitive, Peripheral; Osteosarcoma; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Rhabdoid Tumor; Rhabdomyosarcoma; Sarcoma; Sarcoma, Ewing; Solid tumours; Stomach Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms; Wilms Tumor; Xanthogranuloma, Juvenile
Details